Search Results
Search for other papers by Sarah Theresa Boyle in
Google Scholar
PubMed
Invited Author’s profile Sarah Boyle is an Australian Research Council DECRA Research Fellow at the Centre for Cancer Biology in Adelaide, South Australia. Sarah completed her PhD at the University of Adelaide, investigating the roles of
Search for other papers by Hiroshi Ishikawa in
Google Scholar
PubMed
Evolution and Reproductive Medicine, Medical Mycology Research Center, Chiba University, Chiba, Japan
Fujita Medical Innovation Center Tokyo, Reproduction Center, Tokyo, Japan
Search for other papers by Tatsuya Kobayashi in
Google Scholar
PubMed
Search for other papers by Meika Kaneko in
Google Scholar
PubMed
Search for other papers by Yoshiko Saito in
Google Scholar
PubMed
Search for other papers by Makio Shozu in
Google Scholar
PubMed
Search for other papers by Kaori Koga in
Google Scholar
PubMed
Hereditary leiomyomatosis and renal cell cancer COL4A5/COL4A6 Collagen type 4 alpha 5 chain/collagen type 4 alpha 6 chain Deletions Less than 1% Unknown Alport syndrome Driver gene mutations in UFs MED12 mutations are
National Heart and Lung Institute, Imperial College London, London, UK
Search for other papers by Dorka Nagy in
Google Scholar
PubMed
Search for other papers by Hannah Maude in
Google Scholar
PubMed
Search for other papers by Graeme M Birdsey in
Google Scholar
PubMed
Search for other papers by Anna M Randi in
Google Scholar
PubMed
Search for other papers by Inês Cebola in
Google Scholar
PubMed
and in epithelial-to-mesenchymal transition in cancer ( Fardi et al. 2019 ). ZEB2 was recently shown to be enriched in liver microvascular ECs ( de Haan et al. 2020 ). However, experimental follow-up for the role of ZEB2 in LSECs showed uniform
Centre of Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, Birmingham, UK
Search for other papers by Aqfan Jamaluddin in
Google Scholar
PubMed
Centre of Membrane Proteins and Receptors (COMPARE), Universities of Birmingham and Nottingham, Birmingham, UK
Search for other papers by Caroline M Gorvin in
Google Scholar
PubMed
feeding, which led to the development of the selective 5-HT 2C R agonist lorcaserin. Although lorcaserin was clinically approved to improve weight loss, it was withdrawn in 2020 due to a possible increased occurrence of cancer. An improved understanding of